Arkolith/Insider Trading/ZBIO/Form 4

Enright Patrick G

DirectorZenas BioPharma, Inc. (ZBIO) · full profile →Form 4 · filed Sep 16, 2024
Net Buying
Open-Market Buys
$7.5M
Open-Market Sells
$0
Net Open-Market Flow
$7.5M
Transactions
8
4 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2024Conversion(C)335K——335K
Sep 16, 2024Buy(P)440K$17.00$7.5M775K
Sep 16, 2024Conversion(C)724K——724K
Sep 16, 2024Conversion(C)1.0M——1.7M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2024Conversion(C)6.3M——0
Sep 16, 2024Conversion(C)2.9M——0
Sep 16, 2024Conversion(C)8.7M——0
Sep 12, 2024Grant(A)37K—$037K

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-100333) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML